antibody-drug conjugate

BRIEF: WuXi XDC’s revenue, profit jump in 2024

WuXi XDC Cayman Inc. (2268.HK), a provider of contract services for drug companies, said on Wednesday its revenue and profit rose sharply last year on strong demand for services related…
2268.HK

Recent Articles

RELATED ARTICLES

  1. The latest draft of a U.S. biosecurity law would give drug companies until 2032 to cut their ties with Chinese contract suppliers, allowing WuXi companies time to focus on Europe instead.
    U.S. rethinks timing of biotech crackdown, easing pressure on WuXi family
    2269.HK 2359.HK 2268.HK
  2. WuXi AppTec posts lower profits but avoids more share price pain  
    2359.HK 603259.SHG
  3. Akeso marks profit milestone with swift rights issue
    9926.HK
  4. WuXi AppTec mulls gene unit sale to soften U.S. legal blow
    2359.HK 603259.SHG
  5. Everest Medicines eyes mRNA tumor vaccines as drug valuations rebound
    1952.HK
Discover hidden China stock gems in our weekly newsletter

Follow us

Facebook Twitter Linkedin Weixin Weibo Youtube

Subscribe to Our Free eNewsletter

Subscribe

Check out our content with some of our syndication partners

factiva